Serological indication of chronic inflammatory demyelinating polyneuropathy as an extrahepatic manifestation of hepatitis E virus infection.
Anti-HEV-IgG
CIDP
HEV
Hepatitis E
Myasthenia gravis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 08 2024
20 08 2024
Historique:
received:
17
05
2024
accepted:
13
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Guillain-Barré syndrome and neuralgic amyotrophy have been associated with hepatitis E virus (HEV) genotype 3 infections, while myasthenia gravis (MG) has been associated with HEV genotype 4 infections. However, whether chronic inflammatory demyelinating polyneuropathy (CIDP) is associated with HEV infections has not been conclusively clarified yet. 102 CIDP patients, 102 age- and sex-matched blood donors, 61 peripheral neuropathy patients (non-CIDP patients), and 26 MG patients were tested for HEV and anti-HEV IgM and IgG. Sixty-five of the 102 (64%) CIDP patients tested positive for anti-HEV IgG and one (1%) for anti-HEV IgM. No other patient tested positive for ati-HEV IgM. In the subgroup of CIDP patients with initial diagnosis (without previous IVIG treatment), 30/54 (56%) tested positive for anti-HEV IgG. Anti-HEV rates were significantly lower in blood donors (28%), non-CIDP peripheral neuropathy patients (20%), and MG patients (12%). No subject tested positive for HEV viremia. CSF tested negative for in 61 CIDP patients (54 patients with primary diagnosis). The development of CIDP but not non-CIDP polyneuropathy may be triggered by HEV exposure in an HEV genotype 3 endemic region. The increased anti-HEV seroprevalence in CIDP patients is not a consequence of IVIG therapy.
Identifiants
pubmed: 39164378
doi: 10.1038/s41598-024-70104-3
pii: 10.1038/s41598-024-70104-3
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Hepatitis Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19244Subventions
Organisme : Else-Kröner-Fresenius-Stiftung
ID : 2019:EKFS10
Informations de copyright
© 2024. The Author(s).
Références
Pischke, S. et al. Hepatitis E virus: Infection beyond the liver?. J. Hepatol. 66(5), 1082–1095 (2017).
doi: 10.1016/j.jhep.2016.11.016
pubmed: 27913223
Drave, S. A. et al. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J. Viral Hepat. 23(7), 512–521 (2016).
doi: 10.1111/jvh.12515
pubmed: 26891712
Abravanel, F. et al. Hepatitis E virus quasispecies in cerebrospinal fluid with neurological manifestations. Vaccines 9(10), 1205 (2021).
doi: 10.3390/vaccines9101205
pubmed: 34696313
pmcid: 8537826
Fritz, M. et al. Pathological cerebrospinal fluid findings in patients with neuralgic amyotrophy and acute hepatitis E virus infection. J. Infect. Dis. 217(12), 1897–1901 (2018).
doi: 10.1093/infdis/jiy128
pubmed: 29547884
Fritz-Weltin, M. et al. Acute CNS infections - expanding the spectrum of neurological manifestations of hepatitis E virus?. J Neurol Sci 423, 117387 (2021).
doi: 10.1016/j.jns.2021.117387
pubmed: 33714083
Kamar, N. et al. Hepatitis E virus and neurologic disorders. Emerg. Infect. Dis. 17(2), 173–179 (2011).
doi: 10.3201/eid1702.100856
pubmed: 21291585
pmcid: 3298379
van Eijk, J. J. et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 82(6), 498–503 (2014).
doi: 10.1212/WNL.0000000000000112
pubmed: 24401685
pmcid: 3937863
van Eijk, J. J. J. et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. Neurology 89(9), 909–917 (2017).
doi: 10.1212/WNL.0000000000004297
pubmed: 28768846
Bannasch, J. H. et al. HEV-associated neuralgic amyotrophy: A multicentric case series. Pathogens 10(6), 672 (2021).
doi: 10.3390/pathogens10060672
pubmed: 34070707
pmcid: 8230081
van den Berg, B. et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 82(6), 491–497 (2014).
doi: 10.1212/WNL.0000000000000111
pubmed: 24415572
den Drijver, E. P. M. et al. Evidence for independent hepatitis E virus replication in the brain. Neurol. Neuroimmunol. Neuroinflamm. 8(2), e939 (2021).
doi: 10.1212/NXI.0000000000000939
Lhomme, S. et al. Persistence of hepatitis E virus in the cerebrospinal fluid despite apparently successful ribavirin therapy. J. Antimicrob. Chemother. 77(8), 2300–2303 (2022).
doi: 10.1093/jac/dkac147
pubmed: 35534422
Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. 14(10), 1023–1036 (2015).
doi: 10.1016/S1474-4422(15)00145-3
pubmed: 26376969
Belbezier, A., Deroux, A., Sarrot-Reynauld, F., Larrat, S. & Bouillet, L. Myasthenia gravis associated with acute hepatitis E infection in immunocompetent woman. Emerg. Infect. Dis. 20(5), 908–910 (2014).
doi: 10.3201/eid2005.131551
pubmed: 24751295
pmcid: 4012809
Wang, L. et al. Association of hepatitis E virus infection and myasthenia gravis: A pilot study. J. Hepatol. 68(6), 1318–1320 (2018).
doi: 10.1016/j.jhep.2018.01.040
pubmed: 29681394
Querol, L. et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J. Neurol. 268(10), 3706–3716 (2021).
doi: 10.1007/s00415-020-09998-8
pubmed: 32583051
Kuwabara, S. & Misawa, S. Chronic inflammatory demyelinating polyneuropathy. Adv. Exp. Med. Biol. 1190, 333–343 (2019).
doi: 10.1007/978-981-32-9636-7_21
pubmed: 31760654
Wiesenfarth, M., Stamminger, T., Zizer, E., Tumani, H. & Ludolph, A. C. Neurological manifestation of HEV infection: Still a rare disease entity?. J. Neurol. https://doi.org/10.1007/s00415-023-11985-8 (2023).
doi: 10.1007/s00415-023-11985-8
pubmed: 37737892
pmcid: 10769984
Moret, F. et al. Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy. J. Neurol. Sci. 459, 122959 (2024).
doi: 10.1016/j.jns.2024.122959
pubmed: 38490091
Kraef, C. et al. Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. J. Clin. Virol. 105, 26–30 (2018).
doi: 10.1016/j.jcv.2018.05.013
pubmed: 29860111
Pischke, S. et al. Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients. Infect. Dis. Rep. 4(2), e28 (2012).
doi: 10.4081/idr.2012.e28
pubmed: 24470942
pmcid: 3892632
Mallet, V. et al. Transmission of hepatitis E virus with plasma exchange in kidney transplant recipients: A retrospective cohort study. Transplantation 102(8), 1351–1357 (2018).
doi: 10.1097/TP.0000000000002185
pubmed: 29561324
Ma, Z., de Man, R. A., Kamar, N. & Pan, Q. Chronic hepatitis E: Advancing research and patient care. J. Hepatol. 77(4), 1109–1123 (2022).
doi: 10.1016/j.jhep.2022.05.006
pubmed: 35605741
Faber, M. et al. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J. Viral Hepat. 25(6), 752–758 (2018).
doi: 10.1111/jvh.12868
pubmed: 29377436
Faber, M. S. et al. Hepatitis E virus seroprevalence among adults, Germany. Emerg. Infect. Dis. 18(10), 1654–1657 (2012).
doi: 10.3201/eid1810.111756
pubmed: 23018055
pmcid: 3471611
Svacina, M. K. R. et al. Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies. Eur. J. Neurol. 29(11), 3380–3388 (2022).
doi: 10.1111/ene.15508
pubmed: 35842740